Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers.
- NJACTS Community Engagement Core Available Services
- Why Your Daily Walk Might Not Work as Well if You’re on Metformin.
- In the hallways of Princeton, a fascination with the human mind unlocked the power of deep learning.
- Rutgers Is Awarded $3.75 Million Federal Grant to Prepare Future Special Education Leaders.
Categories
- Community (2,397)
- Covid (993)
- CTO Events (6)
- News (3,035)
- Pilots (21)